Cargando…
Conservative management of endometrial hyperplasia or carcinoma with the levonorgestrel intrauterine system may be less effective in morbidly obese patients
• Endometrial hyperplasia/carcinoma regression rates with LNG-IUS were examined by BMI. • Morbidly obese patients with EH/EHA/EC are more likely to progress. • Despite addition of oral progesterone to LNG-IUS, morbid obesity increases the odds of progression.
Autores principales: | Graul, Ashley, Wilson, Elise, Ko, Emily, Haggerty, Ashley F., Reed, Helen, Koelper, Nathanael, Kim, Sarah H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6148728/ https://www.ncbi.nlm.nih.gov/pubmed/30255125 http://dx.doi.org/10.1016/j.gore.2018.09.001 |
Ejemplares similares
-
The frequency and persistence of lymphedema diagnosis and self-reported symptoms over 5 years in patients with endometrial carcinoma
por: Ritchie, Julia, et al.
Publicado: (2022) -
Patient experiences of conservative treatment for early stage endometrial cancer and endometrial hyperplasia with atypia using levonorgestrel intrauterine device: A qualitative study
por: O'Hara, Montana, et al.
Publicado: (2021) -
The current situation of the levonorgestrel intrauterine system (LNG-IUS) in conservative treatment for patients with early-stage endometrial cancer and atypical hyperplasia
por: Chen, Xiaojun
Publicado: (2019) -
Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia: a national multicentre randomised trial*
por: Ørbo, A, et al.
Publicado: (2014) -
Levonorgestrel-releasing intrauterine system (Mirena) in compare to medroxyprogesterone acetate as a therapy for endometrial hyperplasia
por: Behnamfar, Fariba, et al.
Publicado: (2014)